Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer

BMC Cancer
Maryam Soleimani DodaranAntoine H C van Kampen

Abstract

Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, 30% of ER+ breast cancer patients develop resistance to therapy leading to tumour recurrence. Changes in the methylation profile have been implicated as one of the mechanisms through which therapy resistance develops. Therefore, we aimed to identify methylation loci associated with endocrine therapy resistance. We used genome-wide DNA methylation profiles of primary ER+/HER2- tumours from The Cancer Genome Atlas in combination with curated data on survival and treatment to predict development of endocrine resistance. Association of individual DNA methylation markers with survival was assessed using Cox proportional hazards models in a cohort of ER+/HER2- tumours (N = 552) and two sub-cohorts corresponding to the endocrine treatment (AI or TAM) that patients received (N = 210 and N = 172, respectively). We also identified multivariable methylation signatures associated with survival using Cox proportional hazards models with elastic net regularization. Individual markers and multivariable signatures were compared with DNA methylation profiles generated in ...Continue Reading

References

Jul 1, 1997·Cancer Control : Journal of the Moffitt Cancer Center·G H LymanC Cox
Nov 25, 2004·The Oncologist·Mary Cianfrocca, Lori J Goldstein
Mar 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Hong LiuMina J Bissell
Jul 9, 2010·Bioinformatics·Di WuGordon K Smyth
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Jan 15, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Yi-an ChenRosanna Weksberg
Feb 1, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Eric HervouetRégis Delage-Mourroux
Nov 15, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Kristin E WilliamsKathleen F Arcaro
Mar 29, 2014·Science Translational Medicine·Thushangi N PathirajaSteffi Oesterreich
Jul 25, 2014·Therapeutic Advances in Medical Oncology·Elisavet Paplomata, Ruth O'Regan
Dec 4, 2014·Molecular Oncology·Olafur A StefanssonManel Esteller
Jul 16, 2015·International Journal of Cancer. Journal International Du Cancer·Balázs GyőrffyLibero Santarpia
Oct 8, 2015·BMJ : British Medical Journal·Sepideh SaadatmandMadeleine M A Tilanus-Linthorst
Oct 13, 2015·Molecular and Cellular Endocrinology·Robert ClarkeJ Michael Dixon
Dec 26, 2015·Nucleic Acids Research·Antonio ColapricoHoutan Noushmehr
Jan 16, 2016·Cell Systems·Arthur LiberzonPablo Tamayo
Mar 1, 2011·Journal of Statistical Software·Noah SimonRob Tibshirani
Apr 14, 2016·Epigenetics : Official Journal of the DNA Methylation Society·Dylan E O'SullivanBrock C Christensen
Aug 16, 2017·Seminars in Cancer Biology·Aniruddha ChatterjeeMichael R Eccles
Nov 11, 2017·Nature Communications·Thomas FleischerVessela N Kristensen
Aug 14, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J FerlayF Bray
May 18, 2019·Molecular Oncology·Aurélien LinaresVincent Cavaillès
Dec 1, 2018·Oncology and Therapy·Simon J Johnston, Kwok-Leung Cheung

❮ Previous
Next ❯

Methods Mentioned

BETA
RNA-seq
acetylation
RNAseq
PCR

Software Mentioned

R package survival
Genomic Data Commons
R package mice
R package limma
R package glmnet
IlluminaHumanMethylation450kanno
R package missMethyl
limma
R package TCGAbiolinks
R package edgeR

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
G M H E DackusS C Linn
© 2021 Meta ULC. All rights reserved